https://nucleusrad.com/resources/eclipse-and-mayo-clinic-create-nucleus-radiopharma-to-better-serve-cancer-patients/ 2025-11-06T19:48:54+00:00 https://nucleusrad.com/resources/geoff-johnson-accepts-the-position-of-chief-scientific-officer-at-nucleus-radiopharma/ 2025-11-06T19:50:14+00:00 https://nucleusrad.com/resources/appropriate-use-of-psma-pet-in-clinical-practice/ 2025-11-06T19:54:32+00:00 https://nucleusrad.com/resources/northstar-medical-radioisotopes-announces-supply-agreement-with-nucleus-radiopharma-for-alpha-emitting-therapeutic-radioisotope-actinium-225-ac-225/ 2025-11-06T19:55:16+00:00 https://nucleusrad.com/resources/mayo-clinic-backed-nucleus-radiopharma-raises-56m-in-series-a-to-boost-cdmo-services/ 2025-11-06T20:00:10+00:00 https://nucleusrad.com/resources/fox-chase-cancer-center-invests-in-radiopharmaceuticals-startup/ 2025-11-06T20:05:08+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-secures-56-million-series-a-funding-to-expand-production-of-radiopharmaceutical-treatments-for-cancer-patients/ 2025-11-06T20:08:31+00:00 https://nucleusrad.com/resources/innovationrx-healthtechs-trough-of-disillusionment/ 2025-11-06T20:11:21+00:00 https://nucleusrad.com/resources/with-the-radiopharma-field-booming-rls-plans-to-add-cdmo-services-at-8-us-sites/ 2025-11-06T20:12:04+00:00 https://nucleusrad.com/resources/vista-has-historically-been-known-for-its-large-buyouts-but-the-pe-firm-has-been-doing-a-string-of-smaller-deals-this-year/ 2025-11-06T20:51:28+00:00 https://nucleusrad.com/resources/general-catalyst-combines-with-european-vc-la-famiglia/ 2025-11-20T21:36:03+00:00 https://nucleusrad.com/resources/in-the-fight-against-cancer-its-boom-times-for-radiopharmaceuticals/ 2025-11-20T21:38:05+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-appoints-industry-veteran-mark-przekop-as-chief-operating-officer-to-lead-supply-chain-strategy/ 2025-11-20T21:39:25+00:00 https://nucleusrad.com/resources/eckert-ziegler-to-supply-nucleus-radiopharma-with-therapeutic-radioisotopes-ac-225-and-lu-177/ 2025-11-20T21:42:16+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-appoints-former-mckesson-novo-nordisk-executive-kathy-spencer-pike-as-chief-commercial-officer-to-drive-business-growth/ 2025-11-20T21:44:51+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-announces-appointment-of-chris-mcdonald-from-kite-a-gilead-company-to-board-of-directors/ 2025-11-20T21:46:04+00:00 https://nucleusrad.com/resources/artbio-and-nucleus-radiopharma-announce-collaboration-to-manufacture-gmp-grade-therapeutic-products-containing-radioisotope-pb-212-to-support-emerging-clinical-trials/ 2025-11-20T21:47:18+00:00 https://nucleusrad.com/resources/cdmo-nucleus-radiopharma-links-up-with-artbio-to-help-produce-prostate-cancer-candidate-for-clinical-trials/ 2025-11-20T21:52:24+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-ceo-chuck-conroy-featured-in-cen-article-investment-grows-in-radiopharma-manufacturing/ 2025-11-20T21:56:45+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-secures-series-a-extension-funding-with-astrazeneca-investment/ 2025-11-20T21:57:22+00:00 https://nucleusrad.com/resources/expanding-radiopharmaceuticals-for-cancer-treatment-addressing-supply-and-manufacturing-challenges-charles-conroy/ 2025-11-20T22:00:29+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-expands-radiopharmaceutical-research-development-and-manufacturing-capacity-addressing-nationwide-supply-chain-constraints/ 2025-11-20T22:17:10+00:00 https://nucleusrad.com/resources/astrazeneca-backed-cdmo-nucleus-radiopharma-to-boost-commercial-capacity/ 2025-11-20T22:17:33+00:00 https://nucleusrad.com/resources/clarity-and-nucleus-radiopharma-sign-master-services-agreement-and-cu-67-sar-bispsma-clinical-supply-agreement/ 2025-11-20T22:17:55+00:00 https://nucleusrad.com/resources/backed-by-astrazeneca-this-company-is-helping-radioligand-cancer-therapies-hit-the-shelves/ 2025-11-20T22:18:36+00:00 https://nucleusrad.com/resources/facet-life-sciences-announces-partnership-with-nucleus-radiopharma-as-official-regulatory-partner/ 2025-11-20T22:18:53+00:00 https://nucleusrad.com/resources/a-new-theranostic-system-designed-for-radiopharmas-real-world-demands/ 2025-11-20T22:20:53+00:00 https://nucleusrad.com/blog/what-are-radiopharmaceuticals-a-comprehensive-introduction/ 2025-11-21T00:08:44+00:00 https://nucleusrad.com/wp-content/uploads/radiopharmaceuticals-for-cancer-detection.jpg https://nucleusrad.com/blog/radiotherapies-current-clinical-applications-and-future-directions/ 2025-11-21T00:08:47+00:00 https://nucleusrad.com/wp-content/uploads/Abstract-Cells-1-600x600-1.jpg https://nucleusrad.com/blog/top-5-radiopharmaceutical-manufacturing-and-distribution-challenges/ 2025-11-21T00:08:51+00:00 https://nucleusrad.com/wp-content/uploads/logistics-600x600-1.jpg https://nucleusrad.com/blog/behind-the-scenes-a-day-in-the-life-of-a-radiopharmaceutical-production-manager/ 2025-11-21T00:09:00+00:00 https://nucleusrad.com/wp-content/uploads/Consideration-1-600x600-1.jpg https://nucleusrad.com/blog/outsourcing-your-radiotherapy-manufacturing-here-are-four-things-to-consider/ 2025-11-21T00:09:05+00:00 https://nucleusrad.com/wp-content/uploads/Scientist-1-600x600-1.jpg https://nucleusrad.com/blog/meeting-the-unique-demands-of-radiopharmaceutical-quality-control/ 2025-11-21T00:09:07+00:00 https://nucleusrad.com/wp-content/uploads/Quality-Control-2-1-600x600-1.jpg https://nucleusrad.com/blog/2024-recap-new-possibilities-in-radiopharmaceuticals-from-clinical-trials-to-early-stage-treatment/ 2025-11-21T00:09:10+00:00 https://nucleusrad.com/wp-content/uploads/Science-pharma-2-600x600-1.jpg https://nucleusrad.com/blog/progress-and-predictions-for-radiopharmaceuticals-in-2025/ 2025-11-21T00:09:12+00:00 https://nucleusrad.com/wp-content/uploads/2025-1-600x600-1.jpg https://nucleusrad.com/blog/cmss-cy2025-radiopharma-ruling-what-you-need-to-know/ 2025-11-21T00:09:14+00:00 https://nucleusrad.com/wp-content/uploads/Science-Lightbulb-1-600x600-1.jpg https://nucleusrad.com/blog/key-differences-between-21-cfr-211-and-21-cfr-212-for-radiopharmaceuticals/ 2025-11-21T00:09:15+00:00 https://nucleusrad.com/wp-content/uploads/Abstract-science-600x600-1.jpg https://nucleusrad.com/blog/five-key-considerations-for-the-administration-of-your-radiopharmaceutical-therapy/ 2025-11-21T00:09:18+00:00 https://nucleusrad.com/wp-content/uploads/Radiopharmaceutical-therapy-600x600-1.jpg https://nucleusrad.com/blog/how-to-prepare-your-radiotherapeutic-for-success-at-scale/ 2025-11-21T00:09:22+00:00 https://nucleusrad.com/wp-content/uploads/Radiotherapeutic-for-success-600x600-1.jpg https://nucleusrad.com/blog/get-ahead-of-cmc-hurdles-before-they-derail-your-ind/ 2025-11-21T00:09:29+00:00 https://nucleusrad.com/wp-content/uploads/iStock-2187192364-1000x1000-1.jpg https://nucleusrad.com/blog/why-radiopharmaceutical-supply-chain-diversity-matters/ 2025-11-21T00:09:31+00:00 https://nucleusrad.com/wp-content/uploads/iStock-1331571740-scaled-1.jpg https://nucleusrad.com/blog/five-pitfalls-that-put-radiopharma-programs-at-risk-early/ 2025-11-21T00:09:36+00:00 https://nucleusrad.com/wp-content/uploads/iStock-1309776236.jpg https://nucleusrad.com/blog/how-to-mitigate-cmc-risks-and-avoid-delays-in-ind-stage-radiopharma-development-a-cdmos-perspective/ 2025-11-21T00:09:39+00:00 https://nucleusrad.com/wp-content/uploads/NRP-Blog-2025-Nov-2.webp https://nucleusrad.com/resources/nucleus-radiopharma-appoints-former-fda-commissioner-dr-stephen-hahn-as-ceo-to-scale-patient-access-to-radiopharmaceutical-therapies/ 2025-12-09T18:40:04+00:00 https://nucleusrad.com/blog/ask-the-right-questions-at-every-stage-to-keep-your-radiopharmaceutical-on-track/ 2025-12-10T16:48:40+00:00 https://nucleusrad.com/wp-content/uploads/Ask-the-right-questions.jpg https://nucleusrad.com/blog/how-were-solving-one-of-radiopharmas-biggest-barriers-to-adoption/ 2025-12-10T16:50:14+00:00 https://nucleusrad.com/wp-content/uploads/Radio-pharma.avif https://nucleusrad.com/resources/former-fda-head-stephen-hahn-joins-radiopharmaceuticals-startup-as-ceo/ 2026-03-10T22:37:48+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-taps-former-fda-head-stephen-hahn-as-chief-executive/ 2026-03-10T22:39:46+00:00 https://nucleusrad.com/wp-content/uploads/Group-1000002540.png https://nucleusrad.com/resources/what-the-fdas-new-draft-guidance-means-for-the-radiopharmaceutical-industry/ 2026-04-13T07:14:26+00:00 https://nucleusrad.com/wp-content/uploads/iStock-2193981513.jpg https://nucleusrad.com/resources/the-workforce-behind-radiopharma-isnt-scaling-fast-enough/ 2026-04-13T07:42:18+00:00 https://nucleusrad.com/wp-content/uploads/NRP-Blog-2026-04.13.jpg https://nucleusrad.com/resources/radiopharma-doesnt-fail-in-the-clinic-it-fails-in-execution/ 2026-04-13T07:43:38+00:00 https://nucleusrad.com/wp-content/uploads/NRP-Blog-2026-03.09.jpg https://nucleusrad.com/resources/the-fda-is-getting-ready-for-radiopharma-is-the-industry/ 2026-04-13T07:44:29+00:00 https://nucleusrad.com/wp-content/uploads/NRP-Blog-2026-02.09.jpg https://nucleusrad.com/resources/the-alpha-era-how-2026-could-be-the-breakthrough-year-for-targeted-alpha-therapies/ 2026-04-13T07:44:35+00:00 https://nucleusrad.com/wp-content/uploads/NRP-Blog-2026-01.06-color.jpg https://nucleusrad.com/resources/radiopharma-infrastructure-in-2025-lessons-learned-2026-outlook/ 2026-04-13T07:44:37+00:00 https://nucleusrad.com/wp-content/uploads/NRP-Blog-2025-DEC-10.jpg https://nucleusrad.com/resources/clarity-signs-a-commercial-manufacturing-agreement-for-cu-64-sar-bispsma-with-nucleus-radiopharma/ 2026-04-21T12:54:36+00:00 https://nucleusrad.com/resources/nucleus-radiopharma-secures-50-million-financing-from-orbimed-to-expand-radiopharmaceutical-manufacturing-capacity/ 2026-04-21T12:57:05+00:00